Fig. 1: Osimertinib-resistant and radiation-resistant cancer cells show increased sensitivity to BA treatment.

a Comparison of IC₅₀ values for BA among 21 cancer cell lines derived from the indicated organs and 8 noncancer cell lines as determined by the XTT assay. Data are means from n = 2 independent experiments. b IC₅₀ values for BA as in a showing the overall median values for cancer and noncancer cell lines. The p value was determined by the two-tailed Student’s t test. CellTiter-Glo assay for parental (P-A549) and osimertinib-resistant (O-A549) A549 cells exposed to the indicated concentrations of osimertinib (c) or BA (d) for 48 h. Data are means ± SD from n = 3 independent experiments. **p < 0.01, ***p < 0.001 versus the corresponding value for P-A549 (c) or O-A549 (d) cells (two-tailed Student’s t test). e, f Colony formation assay for parental (P-PANC1) and radiation-resistant (R-PANC1) PANC1 cells, respectively, exposed to 2 Gy of radiation (Rad) or to BA (1200 µM) and cultured for 14 days, as indicated. g, h Colony number determined as in e and f, respectively. Data are means ± SD from three independent experiments, and the p values were determined by one-way ANOVA followed by Tukey’s multiple-comparison test. i Surviving fraction for f, respectively. Data are means ± SD. *p < 0.05 versus BA (two-tailed Student’s t test). j, k CellTiter-Glo assay for P-PANC1 and R-PANC1 cells (j) as well as for parental (P-BxPC-3) and radiation-resistant (R-BxPC-3) BxPC-3 cells exposed to the indicated concentrations of BA for 48 h. Data are means ± SD from n = 3 independent experiments. **p < 0.01, ***p < 0.001 (two-tailed Student’s t test).